James Saller1, Sameer Al Diffalha1, Kevin Neill1, Rahill A Bhaskar1, Cecilia Oliveri2, David Boulware3, Henry Levine2, Isaac Kalvaria4, F Scott Corbett4, Arun Khazanchi4, Jason Klapman5, Domenico Coppola6,7. 1. Departments of Anatomic Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. 2. Center For Digestive Health, Orlando, FL, USA. 3. Biostatistics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. 4. Florida Digestive Health Specialists, Lakewood Ranch, FL, USA. 5. Endoscopy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. 6. Departments of Anatomic Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. domenico.coppola@moffitt.org. 7. Tumor Biology, H. Lee Moffitt Cancer Center and Research Institute, 12902 USF Magnolia Drive, Tampa, FL, 33612, USA. domenico.coppola@moffitt.org.
Abstract
BACKGROUND: CDX-2 is a nuclear homeobox transcription factor not normally expressed in esophageal and gastric epithelia, reported to highlight intestinal metaplasia (IM) in the esophagus. Pathological absence of goblet cells at initial screening via hematoxylin and eosin (HE) and alcian blue (AB) staining results in patient exclusion from surveillance programs. AIMS: This study aimed to determine whether non-goblet cell IM, as defined by CDX-2 positivity, can be considered to be a precursor to Barrett's esophagus (BE). METHODS: This study received IRB approval (17,284). Patients with gastroesophageal reflux disease (n = 181) who underwent upper-gastrointestinal endoscopy with biopsies of the distal esophagus to rule out BE using HE/AB staining and CDX-2 immunostaining were followed for 3 years. Initial and follow-up staining results were evaluated for age/sex. RESULTS: Differences between development of goblet cell IM in CDX-2-negative and CDX-2-positive groups were evaluated. A Kaplan-Meier curve showed that, out of the 134 patients initially positive for CDX-2, 25 (18.7%) had developed goblet cell IM after 2 years and 106 (79.1%) after 3 years. Conversely, of the 47 patients initially negative for CDX-2, 8 (17.9%) developed goblet cell IM after 24 months and only 11 (23.8%) after 40 to 45 months (P = .049; age-adjusted Cox proportional hazard regression model). CONCLUSION: In cases that are initially AB negative and CDX-2 positive, CDX-2 was demonstrated to have a potential prognostic utility for early detection of progression to BE. CDX-2 expression is significantly predictive for risk of goblet cell IM development 40 to 45 months after initial biopsy.
BACKGROUND:CDX-2 is a nuclear homeobox transcription factor not normally expressed in esophageal and gastric epithelia, reported to highlight intestinal metaplasia (IM) in the esophagus. Pathological absence of goblet cells at initial screening via hematoxylin and eosin (HE) and alcian blue (AB) staining results in patient exclusion from surveillance programs. AIMS: This study aimed to determine whether non-goblet cell IM, as defined by CDX-2 positivity, can be considered to be a precursor to Barrett's esophagus (BE). METHODS: This study received IRB approval (17,284). Patients with gastroesophageal reflux disease (n = 181) who underwent upper-gastrointestinal endoscopy with biopsies of the distal esophagus to rule out BE using HE/AB staining and CDX-2 immunostaining were followed for 3 years. Initial and follow-up staining results were evaluated for age/sex. RESULTS: Differences between development of goblet cell IM in CDX-2-negative and CDX-2-positive groups were evaluated. A Kaplan-Meier curve showed that, out of the 134 patients initially positive for CDX-2, 25 (18.7%) had developed goblet cell IM after 2 years and 106 (79.1%) after 3 years. Conversely, of the 47 patients initially negative for CDX-2, 8 (17.9%) developed goblet cell IM after 24 months and only 11 (23.8%) after 40 to 45 months (P = .049; age-adjusted Cox proportional hazard regression model). CONCLUSION: In cases that are initially AB negative and CDX-2 positive, CDX-2 was demonstrated to have a potential prognostic utility for early detection of progression to BE. CDX-2 expression is significantly predictive for risk of goblet cell IM development 40 to 45 months after initial biopsy.
Authors: M Kerkhof; D A Bax; L M G Moons; A J van Vuuren; H van Dekken; E W Steyerberg; E J Kuipers; J G Kusters; P D Siersema Journal: Aliment Pharmacol Ther Date: 2006-12 Impact factor: 8.171
Authors: Famke Aeffner; Kristin Wilson; Nathan T Martin; Joshua C Black; Cris L Luengo Hendriks; Brad Bolon; Daniel G Rudmann; Roberto Gianani; Sally R Koegler; Joseph Krueger; G Dave Young Journal: Arch Pathol Lab Med Date: 2017-05-30 Impact factor: 5.534
Authors: Anna M J van Nistelrooij; Ronald van Marion; Linetta B Koppert; Katharina Biermann; Manon C W Spaander; Hugo W Tilanus; J Jan B van Lanschot; Bas P L Wijnhoven; Winand N M Dinjens Journal: BMC Res Notes Date: 2017-04-04
Authors: Austin M Dulak; Petar Stojanov; Shouyong Peng; Michael S Lawrence; Cameron Fox; Chip Stewart; Santhoshi Bandla; Yu Imamura; Steven E Schumacher; Erica Shefler; Aaron McKenna; Scott L Carter; Kristian Cibulskis; Andrey Sivachenko; Gordon Saksena; Douglas Voet; Alex H Ramos; Daniel Auclair; Kristin Thompson; Carrie Sougnez; Robert C Onofrio; Candace Guiducci; Rameen Beroukhim; Zhongren Zhou; Lin Lin; Jules Lin; Rishindra Reddy; Andrew Chang; Rodney Landrenau; Arjun Pennathur; Shuji Ogino; James D Luketich; Todd R Golub; Stacey B Gabriel; Eric S Lander; David G Beer; Tony E Godfrey; Gad Getz; Adam J Bass Journal: Nat Genet Date: 2013-03-24 Impact factor: 38.330